The world of membranous nephropathy (MN) treatment is undergoing a dramatic shift, with a new wave of innovative therapies poised to revolutionize patient care. According to Spherix Global Insights' Market Dynamix™: Membranous Nephropathy (US) 2025 service, the landscape is evolving rapidly, driven by a desire for more effective and tolerable treatments. But here's where it gets controversial: the traditional approach to MN management is being challenged, and the future of care may not look like the past.
MN, a complex kidney disease, has long been a difficult condition to manage for nephrologists. While ACE inhibitors, ARBs, and SGLT2 inhibitors form the foundation of treatment, many patients eventually require more aggressive immunosuppressive therapies. These include rituximab, corticosteroids, and cytotoxic agents, which are often associated with safety concerns and variable outcomes. As a result, nephrologists are increasingly seeking alternatives that offer better efficacy and tolerability.
One of the most promising new therapies is Biogen's felzartamab, an anti-CD38 monoclonal antibody. In 2025, interest in felzartamab surged as nephrologists recognized its potential in treating resistant MN. They believe it represents a significant advancement over conventional immunosuppressants, offering a more targeted approach. Additionally, physicians anticipate broad patient applicability and rapid adoption following approval.
Vertex Pharmaceuticals' povetacicept is another strong contender in the MN pipeline. This BAFF/APRIL dual-pathway inhibitor has emerged as a differentiated therapy, addressing core disease drivers. Nephrologists expect it to be swiftly adopted once available, as it offers a novel mechanism of action.
Roche/Genentech's obinutuzumab, already familiar to nephrologists due to its broader renal use, is also top-of-mind in MN. Enthusiasm for obinutuzumab is tied to its long-acting B-cell suppression and recent study activity, including new clinical trial initiations and data presented at major nephrology conferences. Some clinicians have already reported early, off-label adoption of obinutuzumab in resistant cases.
These emerging therapies are expected to capture a significant patient share within the first year of launch, with prescribers anticipating comparable adoption trajectories across all three. But the real controversy lies in the broader evolution of step therapy. Over the past year, nephrologists have increasingly shifted treatment algorithms away from steroids and traditional cytotoxic agents, in favor of targeted therapies such as SGLT2 inhibitors and anti-CD20 biologics.
This shift reflects a deliberate effort to minimize steroid exposure and initiate advanced systemics earlier in the disease course. Many physicians cite improved tolerability and the desire for more durable disease control as key drivers of this change. As one nephrologist succinctly put it, 'Less steroids, more SGLT2.'
The momentum behind these new therapies underscores both the significant unmet need and the competitive opportunity ahead. Spherix will continue to track the evolution of the MN landscape through its Market Dynamix™ services, uncovering the opportunities for disruption and innovation. With Market Dynamix™, an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years, insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Spherix Global Insights, a leading independent market intelligence and advisory firm, delivers commercial value to the global life sciences industry, across the brand lifecycle. With a seasoned team of experts, Spherix provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve by leveraging the insights of the extensive Spherix Physician Community.
As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: Client Portal.
